AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3
slide-4
slide-5

Metadoze-IPR 850 Tablet SR

Prescription Icon
Prescription Required

Marketer

Biocon

Salt Composition

Metformin (850mg)

Overview Metadoze-IPR 850 Tablet SR

Metformin extended-release 850mg tablets are prescribed for managing type 2 diabetes. This medication regulates blood glucose, mitigating the risk of diabetes-related complications. It's also indicated for treating Polycystic Ovary Syndrome (PCOS) in women. For optimal absorption and to minimize gastrointestinal upset, Metformin 850mg ER should be taken with food, consistently at the same time daily. Discontinuation should only occur under physician supervision. Maintaining a healthy lifestyle is crucial for diabetes control; diligent adherence to your doctor's dietary and exercise plan is essential during treatment. Commonly reported side effects include nausea, diarrhea, vomiting, gas, weakness, indigestion, stomach discomfort, headache, and decreased appetite. Concurrent use with other diabetes medications, alcohol consumption, or skipped meals can lead to hypoglycemia (low blood sugar). Regular blood glucose monitoring is vital. Prior to commencing treatment, discuss any pre-existing kidney, liver, or heart conditions with your doctor. Pregnant or lactating women must seek medical advice before use. Kidney function will be assessed before treatment initiation. Limit alcohol consumption to reduce the potential for adverse reactions.

Uses of Metadoze-IPR 850 Tablet SR

Management of type 2 diabetes and polycystic ovary syndrome

Major Benefits of Metadoze-IPR 850 Tablet SR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Metadoze-IPR 850 SR tablet whole; avoid chewing, crushing, or breaking it. Administer this medicine with a meal.

Common Side effects of Metadoze-IPR 850 Tablet SR:

  • Diarrhea
  • Headache
  • Vomiting
  • Nausea
  • Flatulence
  • Abdominal discomfort
  • Weakness

How to use Metadoze-IPR 850 Tablet SR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Metadoze-IPR 850 SR Tablet whole; avoid chewing, crushing, or breaking it. Consume with a meal.

How Metadoze-IPR 850 Tablet SR works:

Metformin extended-release 850 mg tablets are a biguanide class antidiabetic drug. Their mechanism of action involves reducing hepatic glucose output, slowing intestinal glucose uptake, and enhancing insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol concurrently with Metadoze-IPR 850 SR Tablets is inadvisable.

PregnancyPregnancySAFE IF PRESCRIBED

Extended-release Metadoze-IPR 850 tablets are typically deemed safe for use during gestation. Preclinical trials in animals have revealed minimal or no negative consequences for fetal development; nevertheless, data from human studies are scarce.

Breast feedingBreast feedingCAUTION

Extended-release Metadoze-IPR 850 mg tablets require careful consideration during lactation. Mothers should discontinue breastfeeding throughout treatment and until the medication is fully cleared from their system.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should exercise caution when using Metadoze-IPR 850 SR tablets; dosage modification may be necessary. A physician's consultation is advised. Metadoze-IPR 850 SR tablets are contraindicated in individuals with severe kidney disease.

LiverLiverUNSAFE

Extended-release Metadoze-IPR 850 tablets are contraindicated for individuals with hepatic impairment and should be omitted. Physician consultation is recommended.

What if you forget to take Metadoze-IPR 850 Tablet SR :

Should you forget a Metadoze-IPR 850 mg Extended-Release Tablet, take it immediately. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Never take a double dose.

Facts to Know About Metadoze-IPR 850 Tablet SR

LabelValue
Type of Compound Guanidine-based hypoglycemic agent
Potential for Dependence None.
Type of Medication Diabetes medication

FAQs on Metadoze-IPR 850 Tablet SR

Individuals with type 2 diabetes exhibit impaired responsiveness to their own insulin. Consequently, blood glucose levels rise. Metadoze-IPR 850 Tablet SR works through multiple mechanisms to lower elevated blood sugar. This medication reduces hepatic glucose production, diminishes intestinal glucose absorption post-prandially, and enhances insulin sensitivity in tissues. This combined action facilitates improved glucose uptake from the bloodstream and optimizes the body's natural insulin response.
Individuals overweight or obese have experienced weight reduction while using Metadoze-IPR 850 SR Tablets. A slight weight decrease may also occur in overweight or obese patients predisposed to diabetes. Insulin-sensitive or insulin-resistant patients might also lose weight. However, self-initiation of this medication for weight management is inadvisable; physician consultation is necessary.
Among initial treatments for elevated blood glucose, Metadoze-IPR 850 Tablet SR effectively manages blood sugar. This medication enhances the body's insulin utilization, reduces hepatic glucose production, and diminishes intestinal glucose absorption. Differing from other oral antidiabetic agents, Metadoze-IPR 850 Tablet SR, when used independently, infrequently leads to hypoglycemia by modulating excessive insulin release. Beyond glycemic control, it also aids in weight management.
Extended-release Metadoze-IPR 850 tablets generally don't induce drowsiness and are usually well-received. Nevertheless, infrequent instances of sleep disturbances and insomnia have been reported with Metadoze-IPR 850 tablet use. Drowsiness can signal a severe adverse reaction known as lactic acidosis, especially prevalent in individuals with impaired kidney function. Consult your physician immediately if fatigue or somnolence develops during Metadoze-IPR 850 tablet treatment.
Administer Metadoze-IPR 850 SR tablets with or following a meal. The tablets should be swallowed whole with water; do not crush or chew them. For once-daily prescriptions, take the tablet in the morning with breakfast. If two tablets are prescribed, take one with breakfast and one with dinner. For three daily doses, administer one with breakfast, one with lunch, and one with dinner. Consuming Metadoze-IPR 850 SR tablets with food mitigates potential gastrointestinal issues such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either produce insufficient insulin or exhibit impaired responsiveness to their naturally produced insulin. This leads to elevated blood glucose levels. Metadoze-IPR 850 Tablet SR employs a multifaceted approach to lower these elevated blood sugar levels. It reduces hepatic glucose production, diminishes intestinal glucose absorption postprandially, and enhances insulin sensitivity in tissues and organs. Consequently, glucose uptake from the bloodstream is improved, and the body's natural insulin response is augmented.
Individuals overweight or obese have experienced weight reduction while taking Metadoze-IPR 850 SR tablets. A slight weight decrease may also occur in overweight or obese individuals predisposed to diabetes. Similarly, insulin-resistant or insulin-sensitive patients might also lose weight. However, self-medicating with this drug for weight loss is inadvisable; physician consultation is necessary.
Metformin extended-release 850 mg tablets are often a primary treatment for patients with elevated blood glucose. This medication manages blood sugar by enhancing the body's sensitivity to its own insulin, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral hypoglycemics, Metformin, when used monotherapy, infrequently leads to hypoglycemia due to its mechanism of action that avoids excessive insulin release. Beyond glycemic control, it also aids in weight management.
Extended-release Metadoze-IPR 850 tablets generally don't induce drowsiness and are typically well-received. Infrequently, however, Metadoze-IPR 850 tablets may lead to sleep disturbances or insomnia. Drowsiness can be a symptom of a severe adverse reaction known as lactic acidosis, especially if kidney function is impaired. Seek medical advice if fatigue or sleepiness develops while using Metadoze-IPR 850 tablets.
Administer Metadoze-IPR 850 SR tablets with or following a meal. Avoid crushing or chewing; ingest whole with water. For once-daily prescriptions, take the tablet in the morning with breakfast. Twice-daily regimens should involve one tablet with breakfast and the second with dinner. Three times daily, distribute the tablets with breakfast, lunch, and dinner. Consuming Metadoze-IPR 850 SR tablets with food mitigates potential gastrointestinal issues such as indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Individuals with type 2 diabetes either insufficiently produce insulin or exhibit impaired responsiveness to their body's insulin production. This results in elevated blood glucose. Metadoze-IPR 850 Tablet SR employs a multifaceted approach to lower these elevated blood sugar levels. It reduces hepatic glucose output, diminishes intestinal glucose absorption postprandially, and enhances insulin sensitivity in tissues. This facilitates improved glucose uptake from the bloodstream. Furthermore, it promotes a more effective response to naturally produced insulin.
Individuals with excess weight or obesity have experienced weight reduction while using Metadoze-IPR 850 SR tablets. A slight weight decrease has also been observed in overweight or obese patients predisposed to diabetes. Furthermore, those with insulin sensitivity or resistance may also lose weight. However, self-initiating this medication for weight management is inadvisable; physician consultation is necessary.
Metformin extended-release 850mg is frequently an initial treatment for hyperglycemia. This medication manages blood glucose by enhancing insulin sensitivity, reducing hepatic glucose production, and limiting intestinal glucose absorption. Differing from other oral hypoglycemics, monotherapy with Metformin extended-release 850mg infrequently leads to hypoglycemia due to its mechanism of action, which avoids excessive insulin release. Beyond glycemic control, it also aids in weight management.
Metadoze-IPR 850 SR tablets typically don't induce drowsiness and are generally well-received. Infrequently, however, Metadoze-IPR 850 SR tablets can lead to sleep disturbances and insomnia. Excessive sleepiness might indicate a severe adverse reaction known as lactic acidosis, especially if renal function is impaired. Consult your physician immediately if fatigue or drowsiness develops during Metadoze-IPR 850 SR treatment.
Administer Metadoze-IPR 850 SR tablets with or following a meal. The tablets should be swallowed whole with water; do not crush or chew them. For once-daily prescriptions, take the tablet in the morning with breakfast. Twice-daily regimens involve one tablet with breakfast and the other with dinner. For three doses daily, distribute them with breakfast, lunch, and dinner. Consuming Metadoze-IPR 850 SR tablets with food mitigates potential gastrointestinal distress, including indigestion, nausea, vomiting, diarrhea, abdominal pain, and anorexia.
Metadoze-IPR 850 Tablet S...
35
MRP 43
18% off